Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001104659-22-089444
Filing Date
2022-08-11
Accepted
2022-08-11 17:18:00
Documents
51
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q ttnp-20220630x10q.htm   iXBRL 10-Q 958706
2 EXHIBIT 31.1 ttnp-20220630xex31d1.htm EX-31.1 12119
3 EXHIBIT 32.1 ttnp-20220630xex32d1.htm EX-32.1 7732
  Complete submission text file 0001104659-22-089444.txt   4031054

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA ttnp-20220630.xsd EX-101.SCH 32090
5 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE ttnp-20220630_cal.xml EX-101.CAL 39159
6 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE ttnp-20220630_def.xml EX-101.DEF 113989
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE ttnp-20220630_lab.xml EX-101.LAB 243015
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE ttnp-20220630_pre.xml EX-101.PRE 200573
45 EXTRACTED XBRL INSTANCE DOCUMENT ttnp-20220630x10q_htm.xml XML 647775
Mailing Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080
Business Address 400 OYSTER POINT BLVD SUITE 505 SAN FRANCISCO CA 94080 6502444990
TITAN PHARMACEUTICALS INC (Filer) CIK: 0000910267 (see all company filings)

EIN.: 943171940 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-13341 | Film No.: 221156960
SIC: 2836 Biological Products, (No Diagnostic Substances)